Osterman Robin, Lewis Daniel, Winhusen Theresa
University of Cincinnati College of Nursing, 3110 Vine Street, Cincinnati, OH 45219, USA.
Addiction Sciences Division, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 3131 Harvey Avenue, Cincinnati, OH 45229, USA.
J Subst Abuse Treat. 2017 Jun;77:150-155. doi: 10.1016/j.jsat.2017.02.003. Epub 2017 Feb 21.
Approximately 35% of pregnant substance users in treatment report alcohol abuse, which increases the risk of fetal alcohol spectrum disorders (FASD) in their offspring. The present study was a preliminary evaluation of the efficacy of motivational enhancement therapy (MET) in decreasing alcohol use in pregnant women attending substance use treatment.
Secondary analysis of a trial evaluating the efficacy of MET, relative to treatment as usual (TAU), in improving treatment outcomes in 200 pregnant substance users. The present study included the 41 women (n=27 MET and n=14 TAU) who reported alcohol use in the 28days prior to randomization. Alcohol and illicit-drug use days were assessed with self-report; illicit drug use was assessed with urine drug screens. All measures were obtained weekly for the 4week active study phase and at 1 and 3month follow-ups.
Significant treatment-by-time interaction effects were found for illicit-drug use days during the active (X=6.89, df=1, p<0.01) and follow-up (X=8.26, df=1, p<0.01) phases and for alcohol use during the follow-up phase (X=13.07, df=1, p<0.001), all reflecting a beneficial effect for MET, relative to TAU. All other treatment effects were non-significant.
These findings suggest that MET may be effective in decreasing alcohol and illicit-drug use in pregnant substance users reporting alcohol use. With 2-5% of US births affected by FASD, future research to replicate these findings seems warranted.
ClinicalTrials.gov http://www.clinicaltrials.gov; Identifier: NCT00078143.
接受治疗的孕期物质使用者中约35%报告有酒精滥用问题,这增加了其后代患胎儿酒精谱系障碍(FASD)的风险。本研究是对动机增强疗法(MET)在减少接受物质使用治疗的孕妇酒精使用方面疗效的初步评估。
对一项试验进行二次分析,该试验评估了MET相对于常规治疗(TAU)在改善200名孕期物质使用者治疗结局方面的疗效。本研究纳入了随机分组前28天内报告有酒精使用的41名女性(n = 27名接受MET,n = 14名接受TAU)。通过自我报告评估酒精和非法药物使用天数;通过尿液药物筛查评估非法药物使用情况。在为期4周的积极研究阶段以及1个月和3个月随访时,每周获取所有测量数据。
在积极治疗阶段(X = 6.89,自由度 = 1,p < 0.01)和随访阶段(X = 8.26,自由度 = 1,p < 0.01),非法药物使用天数以及随访阶段酒精使用天数(X = 13.07,自由度 = 1,p < 0.001)均发现显著的治疗×时间交互效应,所有这些均表明相对于TAU,MET具有有益效果。所有其他治疗效果均不显著。
这些发现表明,MET可能对减少报告有酒精使用的孕期物质使用者的酒精和非法药物使用有效。鉴于美国2 - 5%的出生受FASD影响,未来有必要开展研究以重复这些发现。
ClinicalTrials.gov(http://www.clinicaltrials.gov);标识符:NCT00078143